Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Jianxin You · UNIVERSITY OF PENNSYLVANIA · 2023 · $227,906 — Project Summary Tumor immune suppression represents a major obstacle in achieving effective cancer immunotherapy. The goal of this exploratory project is to develop a novel mRNA-lipid nanoparticle (mRNA-LNP)-based immunotherapy to overcome this challenge in pancreatic cancer, one of the deadliest ma…
Afamefuna Okoye · OREGON HEALTH & SCIENCE UNIVERSITY · 2023 · $840,477 — PROJECT SUMMARY Although the advent of combination antiretroviral therapy (cART) has dramatically improved the prognosis of people living with human immunodeficiency virus (HIV), cART alone cannot eradicate the infection and, therefore, daily treatment must be maintained for life to prevent relapse …
Daniel F. Hoft · SAINT LOUIS UNIVERSITY · 2023 · $667,594 — -γ-producing Th1 cells have been extensively studied for development of novel vaccines and therapeutics against Mycobacterium tuberculosis (Mtb) infection. However, recent studies demonstrate that Mtb-specific Th1 cells alone do not predict protection against tuberculosis (TB). Therefore, although T…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2023 · $2,099,783 — ABSTRACT OVERALL The main goal of our IPCAVD Program grant is to evaluate in humans self-amplifying mRNA (saRNA) vaccines that express two HIV-1 Env-derived protein immunogens that activate and initiate the maturation of VRC01-class B cell receptors (BCRs). The first immunogen, 426c.Mod.Core, was sp…
Mariah A Hassert · UNIVERSITY OF IOWA · 2023 · $69,080 — PROJECT SUMMARY Seasonal influenza A (IAV) and other airborne viral pathogens such as SARS-CoV-2 represent a substantial burden on global public health. While sterilizing immunity can be attained through neutralizing antibodies, seasonal antigenic drift permits viral evasion of humoral immunity, whi…
David K Gifford · THINK THERAPEUTICS, INC. · 2024 · $306,500 — Project Summary We propose to develop a new immunogenicity assay and machine learning based framework for creating tolerization vaccines for autoimmune diseases with improved population coverage. In collaboration with Harvard University and the University of Massachusetts Chan Medical School Diabete…
KEITH R JEROME · FRED HUTCHINSON CANCER CENTER · 2024 · $862,440 — Project Summary Chronic Hepatitis B virus (HBV) infection (CHB) affects hundreds of millions of people across the world. Despite effective vaccines, and antiviral therapies that can suppress viral replication, these infections are largely incurable, and new therapies for CHB are desperately needed. …
Ken A Halvorsen · STATE UNIVERSITY OF NEW YORK AT ALBANY · 2024 · $84,134 — Project Summary Our vision is to develop, apply, and advance new technologies in the broad thematic program of the manipulation of nucleic acids. The research largely focuses on RNA-based applications, which is both driven and enhanced by our unique environment at The RNA Institute, enabling easy co…
Eleftherios Michailidis · EMORY UNIVERSITY · 2024 · $74,814 — Project Summary There are approximately a quarter of a billion people worldwide chronically infected with hepatitis B virus (HBV) who are at risk of developing liver cirrhosis and hepatocellular carcinoma. The loss of life due to HBV-related complications each year is about 820,000 people. At the sa…
Clair Crewe · WASHINGTON UNIVERSITY · 2024 · $622,000 — Project Summary Current paradigms of drug development have made remarkable progress in treating and preventing disease by effecting the function of a single target enzyme, or receptor with specificity. However, many chronic diseases like type 2 diabetes, Alzheimer’s disease, and cardiovascular dise…
Charles M Rice · ROCKEFELLER UNIVERSITY · 2024 · $846,776 — Project Summary The yellow fever 17D live-attenuated vaccine has been administered to millions of people and is a highly successful and safe vaccine providing essentially life-long protection. However, the mechanisms of attenuation are poorly understood, and rare individuals suffer from sometimes f…
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $3,169,510 — Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodies Barton Haynes, MD- PI Sampa Santra, PhD- Co-Investigator The Duke CHAVD has had two major breakthroughs this year in our ability to use rhesus macaques for the study of vaccine-induced bn…
Carlos Enrique Catalano · UNIVERSITY OF COLORADO DENVER · 2024 · $726,000 — PROJECT SUMMARY Newly emerging and long-standing infectious challenges, including arboviruses, Ebola virus and pandemic coronaviruses (CoVs), among others, pose serious public health concerns. Additionally, the potential use of biological agents as weapons of mass destruction poses an ongoing threat…
Kartik Chandran · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $13,946,446 — The overarching goal of PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeu- tics against Diverse Emerging Infectious Threats) is to deliver “plug-and-play” vaccine and therapeutic an- tibody blueprints for emerging enveloped RNA viruses belonging to three families—Nairovi…
GUANGMING ZHONG · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2024 · $2,202,675 — Abstract This proposal is to produce IND-enabling data for supporting clinical trials of an attenuated clone of the mouse-adapted Chlamydia muridarum (CM) as a novel oral vaccine known as intrOv for protecting humans from sexually transmitted infection with Chlamydia trachomatis (CT). Extensive sear…
Ryan Englander · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · 2024 · $53,974 — PROJECT SUMMARY/ABSTRACT Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the United States. Immune checkpoint inhibitors (ICIs) like anti-PD-1 have increased overall survival in NSCLC, but most patients still do not respond to treatment. Cancer vaccines that target tum…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2024 · $797,082 — PROJECT SUMMARY Generation of high affinity antibodies in germinal centers (GCs) is a critical step in a wide variety of clinically relevant processes, from protection against pathogens by prior infection or vaccination to the development of allergies and autoimmune diseases. Antibody affinity matur…
Paul Stephen Keim · NORTHERN ARIZONA UNIVERSITY · 2024 · $1,474,679 — OVERALL Section Title: Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis. SUMMARY Coccidioidomycosis, also known as Valley Fever (VF), is an important fungal disease caused by two different Coccidioides species that results in regional…
NASSER Khaled ALTORKI · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $1,060,438 — Overall Component: Project Summary/Abstract The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer risk. The PI is Dr. Lipkin, an est…
Hannah Frizzell · ORLANCE, INC. · 2024 · $300,000 — PROJECT SUMMARY COVID-19 launched mRNA vaccines to the forefront as the most effective and rapid strategy to respond to the pandemic. mRNA vaccines require formulation in lipid nanoparticles (LNPs) to protect the mRNA from degradation and to achieve efficient intracellular delivery. However, LNP-mRN…